Treatment
Treatment
Advertisement
Cecilia BrownGU Cancer | September 30, 2024
The first-of-its kind clinical trial was presented at the 2024 ASTRO Annual Meeting.
Read More
Cecilia BrownGU Cancer | September 27, 2024
The study investigators say the 5-year survival rate "dramatically exceeds historical standards."
Leah LawrenceGyn-Onc | September 25, 2024
A long-term study points to the importance of evaluating risks and benefits with estrogen versus progesterone with estrogen.
Leah LawrenceGyn-Onc | September 26, 2024
Patients receiving the antibody-drug conjugate showed a 30% reduction in the risk of death compared with chemotherapy.
Leah LawrenceGyn-Onc | September 25, 2024
A new study is shedding light on post-treatment experiences, with many saying they felt they were "left to themselves."
Amanda Brink, DNP, APRN, FNP-BC, AOCNPGI Cancer | September 20, 2024
Oncology nurses can play a key role in improving outcomes and quality of life for patients with metastatic pancreatic cancer.
Katie KoskoGyn-Onc | September 16, 2024
An interim analysis of part 2 of the RUBY trial showed that dostarlimab plus chemotherapy lowered the risk of death by 31%.
Katie KoskoTreatment | September 12, 2024
Learn what a team of researchers found about the impact of this practice.
Prithviraj Bose, MDConferences | September 13, 2024
Dr. Bose shared his insights at the Twelfth Annual Society of Hematologic Oncology Meeting in Houston.
Cancer Nursing Today EditorsGVHD | September 12, 2024
A new study highlights the importance of effective management and close monitoring of GVHD.
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®GVHD | August 22, 2024
It's critical for oncology nurses understand and recognize the 3 atypical lung cGVHD conditions.
Katie KoskoGVHD | August 20, 2024
A small study evaluated the ROCK2 inhibitor for treatment of ocular GVHD because corneal epithelial cells express ROCK2.
Olivia ThomasBreast Cancer | August 19, 2024
Researchers explored the relationship between post-traumatic growth and perceived stress in this population of patients.
Cecilia BrownGyn-Onc | August 15, 2024
The expanded approval is based upon results from part 1 of the phase III RUBY trial.
Teresa Hagan Thomas, PhD, RNPatient Voice | August 14, 2024
More than half of patients did not receive palliative care, but among those who did, 36% received it late.
Cecilia BrownMultiple Myeloma | August 13, 2024
The approval is supported by data from the phase III PERSEUS study.
Katie KoskoGU Cancer | August 12, 2024
The trial is the first to evaluate the combination of an ADC and a TKI in metastatic urothelial carcinoma.
Cecilia BrownTreatment | August 9, 2024
Vimseltinib demonstrated “clinically meaningful functional and symptomatic improvement" in patients with TGCT.
Cecilia BrownNews | August 2, 2024
This form of the drug does not require reconstitution or dilution and can be administered directly from the vial.
Cecilia BrownLeukemia | July 31, 2024
DSP-5336 is an investigational small-molecule inhibitor of the menin and MLL protein interaction.
Advertisement
Advertisement
Advertisement